Free Trial

Roth Capital's Rating of Provectus Biopharmaceuticals on 4/12/2012

On April 12, 2012, Roth Capital updated its outlook on Provectus Biopharmaceuticals (OTCMKTS:PVCT) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Roth Capital

DateCompanyAction
10/9/2025
McEwen Inc. stock logo
MUX
McEwen
Set Price Target
10/9/2025
Primoris Services Co. stock logo
PRIM
Primoris Services
Initiated Coverage
10/6/2025
IPG Photonics Corporation stock logo
IPGP
IPG Photonics
Initiated Coverage
10/7/2025
Blaize Holdings, Inc. stock logo
BZAI
Blaize
Initiated Coverage
10/7/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Set Price Target
10/6/2025
IPG Photonics Corporation stock logo
IPGP
IPG Photonics
Set Price Target
More Ratings From Roth Capital